Patents by Inventor Chi Van Dang

Chi Van Dang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE CELLS WITH ENHANCED CYTOTOXICITY AND METHODS OF USE THEREOF
    Publication number: 20220267781
    Abstract: This disclosure provides methods for enhancing antitumor cytotoxicity of immune cells by introducing to the immune cells a genetic modification that comprises overexpression of RHEB or a functional fragment thereof, overexpression of LAMP 1-RHEB or a functional fragment thereof, overexpression of CA9 or a functional fragment thereof, overexpression of NHE1 or a functional fragment thereof, or combination thereof.
    Type: Application
    Filed: July 24, 2020
    Publication date: August 25, 2022
    Applicants: Ludwig Institute for Cancer Research Ltd, The Wistar Institute
    Inventors: Zandra Walton, Zachary Stine, Yaoyu Gong, Chi Van Dang
  • METABOLIC INHIBITOR AGAINST TUMORS HAVING AN IDH MUTATION
    Publication number: 20130109643
    Abstract: Methods for treating a cancer having a mutant isocitrate dehydrogenase (IDH), including, but not limited to, a malignant low-grade glioma, a secondary glioblastoma, a transforming myeloproliferative disorder (tMPD), and an acute myelogenous leukemia (AML), with a glutaminase inhibitor, including, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), are disclosed.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 2, 2013
    Applicant: The Johns Hopkins University
    Inventors: Gregory Joseph Riggins, Meghan Joyce Seltzer, Takashi Tsukamoto, Chi Van Dang, Ashkan Emadi
  • Methods for identifying anti-tumor and/or anti-angiogenesis drugs with deoxynucleoside 5?-monophosphate N-glycosidase as the target
    Patent number: 7781394
    Abstract: The present invention relates to a novel target for identifying and/or screening antitumor and/or antiangiogenesis agents using the rcl encoded deoxynucleoside 5?monophosphate N-glycosidase.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: August 24, 2010
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Pierre Alexandre Kaminski, Chi Van Dang
  • METHODS FOR IDENTIFYING ANTI-TUMOR AND/OR ANTI-ANGIOGENESIS DRUGS WITH DEOXYNUCLEOSIDE 5'-MONOPHOSPHATE N-GLYCOSIDASE AS THE TARGET
    Publication number: 20080276328
    Abstract: The present invention relates to a novel target for identifying and/or screening antitumor and/or antiangiogenesis agents using the rcl encoded deoxynucleoside 5?monophosphate N-glycosidase.
    Type: Application
    Filed: November 13, 2007
    Publication date: November 6, 2008
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Alexandre Kaminski, Chi Van Dang